STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

12/02/2017


STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

Bad Vilbel, February 12, 2017 –

Due to market rumours, STADA Arzneimittel AG confirms that it has received two legally non-binding expressions of interest regarding a bid for the acquisition of up to 100 percent of the shares in the Company, one of which is from Cinven Partners LLP at an indicative takeover price of Euro 56.00 per STADA share. STADA is currently weighing up its options on how to react in the best interest of the Company. It is not yet possible to foresee whether a takeover offer from Cinven or the other potential bidder will indeed materialise. STADA will keep both the capital markets and the public updated on tangible development in this regard, in line with the applicable legal requirements.


Contact:
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de

Download in PDF format

Share:

Related Posts

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018
The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2018.
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH